The first feline model of human Congenital Erythropoietic Porphyria (CEP) due to deficient uroporphyrinogen III synthase (URO-synthase) activity was identified by its characteristic clinical phenotype and confirmed by biochemical and molecular genetic studies. The Proband, an adult domestic shorthair cat, had dark red urine and brownish discolored teeth with red fluorescence under UV light.
INTRODUCTION MATERIALS AND METHODS

The Proband
The Proband was a neutered 10 year old male domestic shorthair cat who was referred from Amherst, Wisconsin because the cat had brownish discolored teeth. When examined, his teeth fluoresced pink, but no other clinical signs were noted. No family history was available as the Proband was adopted at nine years of age. Complete blood cell counts and blood cell morphology were normal except for a mild normoblastosis, basophilic stipling, and polychromasia. Blood lead levels were negative, and all other routine laboratory analyses were within normal limits. Fresh blood and urine samples were obtained from the Proband and healthy adult cats. Animal procedures were approved by the University of Pennsylvania Institutional Animal Care and Use Committee.
Biochemical Studies
Fresh frozen erythrocytes (3-5 ml) from the Proband and healthy wild-type cats were lysed in 3 volumes of 50 mM K-Hepes, pH 7.5, 0.02% sodium azide, 0.1% Triton X-100, and 1 mM DTT and centrifuged at 10,000 x g for 10 min. URO-synthase and hydroxymethylbilane synthase (HMB-synthase) activities were measured in the cleared erythrocyte lysates from the Proband and wild-type cats as previously described (26, 27) . For porphyrin analyses, urine, plasma and erythrocyte lysates were deproteinized by addition of 20% TCA /DMSO 1:1 (v/v) followed by centrifugation at 10,000 x g for 10 min. Porphyrin isomers in deproteined samples were resolved and quantitated by ultraperformance liquid chromatography with fluorescence monitoring as previously described (1) . The levels of the porphyrin precursors, aminolevulinic acid (ALA) and porphobilinogen (PBG), were determined in urine from the Proband and wild-type adult cats using the ALA/PBG Column Test kit (Bio-Rad Laboratories, Hercules, CA) according to the manufacturer's instructions.
Molecular Analyses
Genomic DNA was isolated from whole blood obtained from the Proband and wild-type cats using the Puregene ® Genomic DNA Purification kit (Gentra Systems, Minneapolis, MN). The feline UROS
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gene was amplified from genomic DNA using the HotStarTaq ® MasterMix (Qiagen, Valencia, CA) by the polymerase chain reaction (PCR) with the primers and annealing temperatures listed in Supplemental Table 1 . Briefly, PCR amplification was performed using the following sequential steps: 95°C for 15 min, then 31 cycles of amplication with denaturation at 95°C for 30 sec, extension at the annealing temperature (Supplemental Table 1 ) for 30 sec, a 1°C/s ramp to 72°C, followed by 72°C for 30 sec, and then a final extension at 72°C for 10 min.
RNA was extracted, purified and retrotranscribed in one step from liver and spleen as previously described (1). The primers for each cDNA region are listed in Supplemental Table 1B . The cDNA and genomic sequences and electropherogram traces were compared using CodonCode Aligner (CodoCode Corp., Dedham, MA). The individual amplicons were sequenced using the amplification primers on an Applied Biosystems Model 3730xl DNA Analyzer (Foster City, CA).
Since the cat UROS genomic sequences (GenBank accession numbers ACBE01376257 and ACBE01376259) lacked identification of the housekeeping and erythroid-specific exons and promoters, and since the predicted intron/exon boundaries had been assigned by homology to those in other organisms, the feline genomic organization and sequence were determined by sequencing the UROS gene in the domestic shorthair cat using primer selection based on homology with the human UROS gene structure. For delineation of the feline gene's intron-exon boundaries, the sequences of reversetranscribed feline erythroid and housekeeping UROS mRNAs were determined and compared with the exon-flanking intronic regions using ClustalW (MacVector, MacVector, Inc., Cary, NC). The genomic exon 1 and 2 with flanking sequences and the housekeeping and erythroid-specific cDNA sequences were deposited in GenBank (http://www.ncbi.nlm.nih.gov/gene/) as accession numbers GB #1 to 4 pending.
To determine if the two missense mutations detected in the Proband's URO-synthase sequence were polymorphisms, their presence was evaluated in 100 normal alleles from domestic shorthair cats. For the exon 3 c.140C>T (p.S47F) mutation, a region of 153 bp was amplified with primers FmU-S47F-F and FmU-S47F-R (Supplemental FmU-G111S-F and FmU-G111S-R (Supplemental Table 1 ) and digested with HaeIII (New England Biolabs). Absence of the mutation yielded HaeIII fragments of 100 and 50 bp, while the 150 bp amplicon was not digested when the mutation was present (Supplemental Table 1 ).
Prokaryotic Expression of the Recombinant Feline URO-Synthase Missense Mutations
The full-length feline URO-synthase coding cDNA was amplified (see primers in Supplemental Table   1 ) and subcloned into the pSU vector as described (1), and the c. Scientific, Pittsburgh, PA), 330 mg/ml lysozyme, and 1 μM leupeptin and then lysed by three cycles of freeze/thaw in ethanol/dry ice and a 37°C water baths and then centrifuged at 10,000 x g for 30 min. The expressed feline enzyme was purified by two consecutive affinity chromatographic steps on nickelagarose resin (IMAC Sepharose High Performance, GE Healthcare, Piscataway, NJ). The eluate was concentrated and the buffer exchanged to 50 mM HEPES, pH 7.4, 100 mM NaCl and 5 mM TCEP using an Amicon Ultra-15 Centrifugal Filter Unit, 10 kDa cutoff (Millipore, Billerica, MA). URO-synthase activity was measured as described previously (27) . One unit of activity is that amount of enzyme producing 1 nmole of uroporphyrin III in one hour under the conditions of the assay.
Thermostability Studies
Following expression of the mutant and wild-type constructs as described above, purified enzyme preparations were adjusted to 50 mM HEPES, pH 7.4, 100 mM NaCl and 5 mM DTT and aliquots were UNCORRECTED PROOF Molecular Medicine www.molmed.org incubated at 50°C for up to 1 h. Aliquots were removed to ice at regular intervals and URO-synthase activity was determined.
Structural Studies
The three dimensional structures of the feline wild-type and mutant URO-synthase enzymes were generated using the SWISS-MODEL server (swissmodel.expasy.org) (28) . Four separate feline UROsynthase structures were modeled for the wild-type, p.S47F, p.G111S, and doubly mutant p.S47F/G111S enzymes using the crystal structure of human URO-synthase (PDB entry 1JR2A) as the template. The 
RESULTS
Biochemical Studies
Urinary ALA and PBG concentrations were not increased in the Proband, while the levels of URO I and COPRO I were markedly elevated, ~2,600-and ~245-fold greater than the respective mean wild-type values ( Table 1 ). The plasma levels of URO I and COPRO I also were markedly increased over respective wild-type mean levels, ~11,000-and ~5,300-fold, respectively (Table 2 ). In erythrocytes, URO I and COPRO I were elevated ~180-and ~2,200-fold, respectively ( Table 2 ). Protoporphyrin IX was not elevated in urine or blood. As shown in Table 3 , the URO-synthase enzymatic activity in erythrocytes from the Proband was less than 1% of the mean wild-type feline activity, while the HMB-synthase levels were increased several fold, confirming the clinical and biochemical diagnosis of CEP.
Molecular Analyses
The exon/intron structure of the feline gene was found to be identical to that of the previously reported mouse and human URO-synthase genes (14, 15) and the 5'UTRs of each transcript and approximate location of the housekeeping and erythroid promoters were identified (Supplemental Table   2 ). Since the 5'-ends of the housekeeping exon 1 and the erythroid-specific exon 2A were sequenced using exonic primers, the transcription start sites in the cat were not determined. Of note, the full length UROS polypeptide was one amino acid shorter than in primates and rodents, ending (as in canines) in one cysteine instead of two.
For feline HMB-synthase, sequence analysis of the entire coding region and flanking intronic sequences of the Proband and wild-type feline genes revealed normal sequences with no exonic polymorphisms when compared to the recently deposited hepatic and erythroid feline sequences (GenBank Accession numbers CQ850461-4) (1).
URO-synthase Mutation Detection and Expression
Sequencing the Proband's URO-synthase gene revealed two homozygous missense mutations: a C to T transition at position 140 in exon 3 (c.140C>T) predicting the substitution of a phenylalanine for a UNCORRECTED PROOF Molecular Medicine www.molmed.org serine residue (p.S47F) and a G to A transition at position 331 in exon 6 (c.331G>A) predicting the replacement of a glycine by a serine residue (p.G111S). Analysis of 100 feline wild-type alleles for the c.140C>T and c.331G>A mutations did not detect these changes, suggesting that they were not common polymorphisms.
Each mutation was introduced separately and together into the feline URO-synthase full-length cDNA and expressed in E. coli. The purified feline p.S47F enzyme had normal activity, while the feline p.G111S enzyme had ~60% of expressed wild-type activity (Table 4) . When the cDNA construct with both mutations was expressed, the purified doubly mutant (p.S47F/G111S) enzyme's activity was markedly reduced to ~20% of expressed wild-type activity. However, the yield of purified enzyme was only ~2% of the purified expressed wild-type enzyme (Table 4) . When incubated at 50°C at pH 7.4 for 15 min, the wild-type enzyme retained 28% of initial activity, whereas the p.S47F, p.G111S, and doubly mutant p.S47F/G111S enzymes had 11, 0.1, and 0.3% of their initial activities, respectively (Table 4 ).
Molecular Modeling of the Feline Wild-type and Mutant Enzymes
The three-dimensional structures of the wild-type and three mutant feline URO-synthase enzymes (p.S47F, p.G111S, and p.S47F/G111S), were modeled as described in Materials and Methods. The total energies calculated for the wild-type, p.S47F, p.G111S, and p.S47F/G111S structure models were 8802, 8790, 7512, and 6950 kJ/mol, respectively, consistent with the observed decreased relative stability of the p.G111S and doubly mutant proteins. Three distinct clusters of three amino acids each exhibited positional differences compared to the wild-type feline structure. Cluster 1 was located in the previously identified active site (16, 18, 29) in the cleft between domains 1 and 2 and contained residues Asp8, Leu36 and Lys170. Cluster 2 was located in domain 1 directly above the hinge beta sheet and contained residues Ser47 or Phe47, Asp77, and Lys79. Cluster 3 contained residues Lys88, Ile110 and G111 or S111, and was located in domain 1 between two alpha helices whose connecting vertex contained the Asp77 and Lys79 of Cluster 2. For Cluster 1, the movements of the three residue's backbone and side-chain atoms (not including hydrogens) were modest, being greatest between the wild-type and the p.S47F/G111S structures (totaling 2.76Å; Data not shown), and were essentially uninfluenced by the presence of the UNCORRECTED PROOF Molecular Medicine www.molmed.org p.G111S mutation alone. Larger atomic movements were noted in Cluster 2 (totaling 15.71Å) and were greatest between residue atoms for the p.S47F structure compared to the p.G111S structure (Data not shown). As in Cluster 1, the cause of the movements could be attributed almost completely to the substitution of the bulky Phe47 substitution. In contrast, for Cluster 3, a unique interaction with Cluster 2 was observed. This was most notable for residue 111 where the positions of the Ser111 backbone atoms in the double mutant structure (Fig 1C) were intermediate between their positions in the p.S47F (Fig 1A) and p.G111S mutant structures (Fig 1B) . The greatest total atomic movement in Cluster 3 (4.86Å; Data not shown) was between the p.S47F and p.G111S structures. Some movement was also seen for residue Leu112 near this cluster (data not shown). and had increased URO and COPRO concentrations were reported as having a "congenital porphyria" or CEP (24, 25, 30, 31) . However, the feline disease was inherited as an autosomal dominant trait, as it was in some pig models (21, 23, 32, 33) , whereas in humans and cattle the disease is inherited only as an autosomal recessive trait (2, 22, 32, 34) . Recently, this conundrum was clarified, as cats with the CEP-like phenotype and autosomal dominant inheritance were shown to actually have acute intermittent porphyria (AIP) (1). The AIP cats had elevated urinary ALA and PBG levels, half-normal activities of HMBsynthase activity in erythrocytes and tissues, and normal or slightly elevated erythrocyte URO-synthase activities (1).
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In the course of evaluating additional cats referred with the CEP-like phenotype, the Proband reported here was identified. In urine, he had markedly elevated URO I and COPRO I, but normal levels of ALA and PBG, and normal erythrocyte HMB-synthase activity (Tables 1-3) . Although expressing urinary URO
III and COPRO III as fold increases over wild-type gives the impression of large (25-200)-fold increases,
it should be noted that wild-type levels are very low and the 200-fold increase only resulted in 3.5% III isomer compared to the total -the vast majority being the I isomer (Table 1) . Thus the III isomer elevation was not a significant contributor to the porphyria. Even less III isomer was observed in erythrocytes and plasma; 0.9% and 0.0%, respectively (Table 2 ). This contrasts with much higher percentages (65% and 31% in eythrocytes and urine) for the AIP cats. His erythrocyte URO-synthase activity was nearly absent, consistent with the diagnosis of CEP (Table 3) . The clinical and biochemical features of the AIP and CEP cats are summarized in Table 5 . Mutagenesis and expression studies of the feline URO-synthase mutant constructs indicated that the purified p.S47F enzyme had normal specific activity and modest thermolability, whereas the purified p.G111S mutant enzyme had ~60% of wild-type activity and was markedly more thermolabile (Table 4) .
Notably, expression of the disease-causing allele having both the c.140C>T and c.331G>A mutations resulted in an enzyme protein (p.S47F/G111S) that had markedly reduced activity compared to the p.G111S enzyme, but similar thermolability (Table 4) . Of particular note, the yield of the purified expressed p.S47F/G111S active enzyme was ~2% of wild-type, suggesting that the doubly mutant enzyme did not fold properly and/or was susceptible to intracellular degradation.
Modeling studies comparing the predicted wild-type and mutant enzyme structures were informative since the feline and human enzymes had 86% amino acid identity. Although the p.S47F substitution generated the greatest motion in the three affected residue clusters, it alone had no effect on the mutant enzyme's activity but reduced its thermostability by ~50%. In contrast, the p.G111S substitution had a major effect on both the p.G111S enzyme's activity and thermostability. Glycine is known to contribute to turn formation in protein structures and indeed, G111 is located at the apex of a turn between two helicies in the enzyme. Thus, its replacement would be expected to have a deleterious effect on the mutant enzyme's structure and function. Modeling of the p.S47F/G111S mutant enzyme revealed that the two substitutions interacted to form a unique structure not present in the predicted structures for either single mutation (Fig 1) . This interaction presumably resulted in the markedly reduced specific activity of the doubly mutant enzyme compared to either single mutant enzyme. Furthermore, the calculated total GROMAS energy (36) (and therefore predicted stability) for the p.S47F/G111S mutant was the lowest of all four predicted enzyme structures, consistent with the purified doubly mutant enzyme's reduced yield.
Thus, the two amino acid substitutions in the enzyme acted synergistically to inactivate and destabilize the doubly mutant monomeric enzyme.
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Neither the p.S47F nor p.G111S mutations have been reported in humans with CEP. Interestingly, a different mutation in codon 47 (c.139T>C, p.S47P) was reported in a CEP family in which several homozygous siblings had severe manifestations (37), consistent with its in vitro expression of <3% of expressed wild-type activity in vitro and <0.3% of wild-type activity in patient erythrocytes. In contrast to the phenylalanine substitution in the CEP cat, the proline substitution in human CEP, a residue known to significantly alter protein structure, markedly decreased the human enzyme's function.
In summary, the cat described here represents the first biochemically and genetically proven feline 
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TABLES
